Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Lonnel_Coats
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:CUSIP |
528872104
|
| gptkbp:focusArea |
rare diseases
cardiometabolic diseases |
| gptkbp:foundedYear |
1995
|
| gptkbp:hasCompany |
gptkb:Lexicon_Pharmaceuticals,_Inc.
|
| gptkbp:headquartersLocation |
gptkb:The_Woodlands,_Texas,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US5288721048
|
| gptkbp:listedOn |
gptkb:NASDAQ_Global_Market
|
| gptkbp:numberOfEmployees |
approximately 200
|
| gptkbp:product |
INPEFA (sotagliflozin)
XERMELO (telotristat ethyl) |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:LXRX
|
| gptkbp:website |
https://www.lexpharma.com/
|
| gptkbp:bfsParent |
gptkb:Lexicon_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ:LXRX
|